iFlop Goldtooth® Enabled, page-65

Most spec stocks do not have enough revenue to cover running costs....so more a case of people believing enough to want to stump up cash. Look at RAP as case in point or FBR.

I don't believe in the Convertible Note or BoD salaries, but I believe otherwise in the tech and the strategy, and efforts to improve project / product delivery processes.

Soon the dreaded Convertible Note will out of the way and hopefully BoD salaries realigned to focus on right balance of share incentives vs cash salary component consistent with stage of development (which will help sentiment towards the stock). And lastly not being over aggressive on revenue targets as I actually think they are doing ok progress wise but just shot themselves in the foot with over aggressive revenue targets (which was also reflective of lack of clear coherent strategy prior to coming on board...e.g. Leap-in deal....which addressed in spades since Martin come on board 11 months ago).

Yes this is a risky stock but can't think of many better risk/reward plays for stocks under $20m than XPED personally.

And thanks Scar for your continued sharing of research as just reinforces my interest in this stock.